{"id":220383,"date":"2026-08-27T10:03:11","date_gmt":"2026-08-27T04:33:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=220383"},"modified":"2026-08-27T10:03:13","modified_gmt":"2026-08-27T04:33:13","slug":"symbiotec-pharmalab-initial-public-offering-final-day-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/","title":{"rendered":"Symbiotec Pharmalab Initial Public Offering Closes Today: Issue Subscribed 5.60x as NII Demand Surges"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Symbiotec Pharmalab initial public offering closes today, Aug 27, 2026. Subscribed 5.60x by end of Day 3. NII 12.83x, employee 6.21x, retail 5.34x, QIB 0.62x.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Symbiotec Pharmalab&#8217;s Rs 1,757 crore initial public offering closes today, August 27, 2026, after picking up considerable momentum through its subscription window. The issue was subscribed 5.60 times overall by the end of Day 3 trading on August 26, with non-institutional investors (NIIs) leading demand at 12.83 times, followed by employees at 6.21 times and retail investors at 5.34 times.<\/p>\n<\/div>\n<p>Symbiotec Pharmalab Limited&#8217;s Rs 1,757 crore initial public offering closes today, August 27, 2026, marking the final day of a subscription window that opened on August 24. The issue saw a sharp rise in demand through Day 3 of bidding, taking the overall subscription to 5.60 times by 5:09 PM on August 26, 2026, according to the latest available subscription data.<\/p>\n<p>The public issue received bids for 6,97,96,905 shares against 1,24,60,533 shares offered to investors, with the number of applications reaching 19,72,612. Non-institutional investors (NIIs) led the bidding at 12.83 times, followed by the employee category at 6.21 times and retail investors at 5.34 times. The qualified institutional buyer (QIB) portion, excluding the anchor allocation, stood at 0.62 times as of the same update.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=symbiotec-finalday\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#About_Symbiotec_Pharmalab\" title=\"About Symbiotec Pharmalab\">About Symbiotec Pharmalab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#Symbiotec_Pharmalab_IPO_Key_Details\" title=\"Symbiotec Pharmalab IPO: Key Details\">Symbiotec Pharmalab IPO: Key Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#Symbiotec_Pharmalab_Financial_Performance\" title=\"Symbiotec Pharmalab Financial Performance\">Symbiotec Pharmalab Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#What_Happens_After_the_Issue_Closes_Today\" title=\"What Happens After the Issue Closes Today\">What Happens After the Issue Closes Today<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#FAQs_on_Symbiotec_Pharmalab_Initial_Public_Offering\" title=\"FAQs on Symbiotec Pharmalab Initial Public Offering\">FAQs on Symbiotec Pharmalab Initial Public Offering<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#What_is_the_Symbiotec_Pharmalab_IPO_subscription_status_on_the_final_day\" title=\"What is the Symbiotec Pharmalab IPO subscription status on the final day?\">What is the Symbiotec Pharmalab IPO subscription status on the final day?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#When_does_the_Symbiotec_Pharmalab_IPO_close\" title=\"When does the Symbiotec Pharmalab IPO close?\">When does the Symbiotec Pharmalab IPO close?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#What_does_Symbiotec_Pharmalab_manufacture\" title=\"What does Symbiotec Pharmalab manufacture?\">What does Symbiotec Pharmalab manufacture?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#When_will_Symbiotec_Pharmalab_shares_be_allotted_and_listed\" title=\"When will Symbiotec Pharmalab shares be allotted and listed?\">When will Symbiotec Pharmalab shares be allotted and listed?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#What_is_Symbiotec_Pharmalabs_financial_performance\" title=\"What is Symbiotec Pharmalab&#8217;s financial performance?\">What is Symbiotec Pharmalab&#8217;s financial performance?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-initial-public-offering-final-day-2026\/#Is_the_Symbiotec_Pharmalab_IPO_oversubscribed\" title=\"Is the Symbiotec Pharmalab IPO oversubscribed?\">Is the Symbiotec Pharmalab IPO oversubscribed?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Symbiotec_Pharmalab\"><\/span><strong>About Symbiotec Pharmalab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Symbiotec Pharmalab&#8217;s live subscription status on the Univest Screener<\/strong><\/a><\/p>\n<p>Symbiotec Pharmalab Limited, incorporated in 2002, operates in the pharmaceutical and biotechnology sector, developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company has built its operations around a backward-integrated manufacturing model and holds a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs as of Fiscal 2026, making it one of the few companies globally present across the top 10 such APIs.<\/p>\n<p>The company&#8217;s manufacturing facilities are concentrated in Madhya Pradesh, with its Rau and Pithampur facilities approved by the US FDA, WHO-GMP, and EU-GMP. Symbiotec Pharmalab serves more than 50 domestic and 150 export customers across North America, Europe, and Asia as of March 31, 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Symbiotec_Pharmalab_IPO_Key_Details\"><\/span><strong>Symbiotec Pharmalab IPO: Key Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr>\n<th style=\"background: #1F4E79; color: #fff; padding: 8px 12px; text-align: left;\">Parameter<\/th>\n<th style=\"background: #1F4E79; color: #fff; padding: 8px 12px; text-align: left;\">Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">IPO Open Date<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">August 24, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">IPO Close Date<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">August 27, 2026 (today)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Price Band<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Rs 938 to Rs 988 per share<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Total Issue Size<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Rs 1,757 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Overall Subscription (Day 3, 5:09 PM Aug 26)<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">5.60x<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">NII Subscription<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">12.83x<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Employee Subscription<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">6.21x<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Retail Subscription<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">5.34x<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">QIB Subscription (ex-anchor)<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">0.62x<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Anchor Investor Allocation<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Rs 526.20 crore (53,25,909 shares)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Total Applications<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">19,72,612<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Listing Exchanges<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">NSE and BSE<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Tentative Allotment Date<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">August 28, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">Tentative Listing Date<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #ddd;\">September 1, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Symbiotec_Pharmalab_Financial_Performance\"><\/span><strong>Symbiotec Pharmalab Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Symbiotec Pharmalab&#8217;s Total Income for FY26 was Rs 872.26 crore, up from Rs 755.98 crore in FY25 and Rs 723.33 crore in FY24. Profit After Tax for FY26 stood at Rs 109.90 crore, compared to Rs 96.79 crore in FY25 and Rs 100.06 crore in FY24. EBITDA for FY26 was Rs 231.97 crore, reflecting steady margin improvement over the past three fiscal years.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Happens_After_the_Issue_Closes_Today\"><\/span><strong>What Happens After the Issue Closes Today<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>With the subscription window closing today, the basis of allotment for Symbiotec Pharmalab is expected to be finalised on August 28, 2026. Successful applicants will see shares credited to their demat accounts, while refunds will be processed for unsuccessful or partially successful bids. The company&#8217;s shares are tentatively scheduled to list on the NSE and BSE on September 1, 2026.<\/p>\n<p>Univest does not publish grey market premium figures. Grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified, or endorsed by SEBI, NSE, or BSE, can vary widely between trackers, and is not always accurate. Investors interested in checking informally reported premium levels may refer to independent trackers such as InvestorGain.com or Chittorgarh.com, treating this data as supplementary only.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Symbiotec Pharmalab&#8217;s initial public offering has closed its subscription window today with strong overall demand, led by non-institutional investors. With allotment expected on August 28 and listing tentatively scheduled for September 1, 2026, investors should track the registrar&#8217;s allotment status page for updates on their application. This article does not constitute subscription advice. Consult a SEBI-registered financial advisor before applying for any IPO.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track IPO allotment and listing updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Symbiotec_Pharmalab_Initial_Public_Offering\"><\/span><strong>FAQs on Symbiotec Pharmalab Initial Public Offering<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Symbiotec_Pharmalab_IPO_subscription_status_on_the_final_day\"><\/span><strong>What is the Symbiotec Pharmalab IPO subscription status on the final day?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> By the end of Day 3 trading on August 26, 2026, Symbiotec Pharmalab&#8217;s initial public offering was subscribed 5.60 times overall, with NII demand at 12.83 times, employee subscription at 6.21 times, and retail investors at 5.34 times.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_does_the_Symbiotec_Pharmalab_IPO_close\"><\/span><strong>When does the Symbiotec Pharmalab IPO close?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Symbiotec Pharmalab initial public offering closes today, August 27, 2026, marking the final day of its three-day subscription window that opened on August 24.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Symbiotec_Pharmalab_manufacture\"><\/span><strong>What does Symbiotec Pharmalab manufacture?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Symbiotec Pharmalab manufactures active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products, holding a global leadership position in corticosteroid and steroidal-hormone APIs by volume.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_will_Symbiotec_Pharmalab_shares_be_allotted_and_listed\"><\/span><strong>When will Symbiotec Pharmalab shares be allotted and listed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The basis of allotment for Symbiotec Pharmalab is expected to be finalised on August 28, 2026, with shares tentatively scheduled to list on the NSE and BSE on September 1, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Symbiotec_Pharmalabs_financial_performance\"><\/span><strong>What is Symbiotec Pharmalab&#8217;s financial performance?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Symbiotec Pharmalab reported Total Income of Rs 872.26 crore and Profit After Tax of Rs 109.90 crore for FY26, up from Rs 755.98 crore and Rs 96.79 crore respectively in FY25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Symbiotec_Pharmalab_IPO_oversubscribed\"><\/span><strong>Is the Symbiotec Pharmalab IPO oversubscribed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, as of the end of Day 3 (August 26, 2026), the Symbiotec Pharmalab initial public offering was subscribed 5.60 times overall, indicating the issue was oversubscribed ahead of its final day of bidding.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Symbiotec Pharmalab initial public offering closes today, August 27, 2026. The issue was subscribed 5.60 times by the end of Day 3, led by strong NII demand at 12.83 times.<\/p>\n","protected":false},"author":28,"featured_media":220382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1281],"tags":[1015],"class_list":["post-220383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","tag-ipo"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["220382"],"_edit_lock":["1787805197:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["1281"],"rank_math_seo_score":["70"],"rank_math_title":["Symbiotec Pharmalab Initial Public Offering Final Day: Subscribed 5.60x"],"rank_math_description":["Symbiotec Pharmalab initial public offering closes today, August 27, 2026. The issue was subscribed 5.60 times by the end of Day 3, led by strong NII demand at 12.83 times."],"rank_math_focus_keyword":["Symbiotec Pharmalab initial public offering"],"rank_math_robots":["a:1:{i:0;s:7:\"noindex\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["40093"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/symbiotec-pharmalab-initial-public-offering-final-day-2026.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/220383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=220383"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/220383\/revisions"}],"predecessor-version":[{"id":220455,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/220383\/revisions\/220455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/220382"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=220383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=220383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=220383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}